糖尿病患者牙周炎治疗后炎症状况的改善:随机对照试验的元分析
Davi da Silva Barbirato1,2, Natasha Soares Nogueira3, Taísa Coelho Guimarães3
1Division of Periodontics, Dental School, Federal University of Rio de Janeiro, CidadeUniversitária, 325 Prof. Rodolpho Paulo Rocco St, Rio de Janeiro, RJ, Brazil. davibarbirato@gmail.com.
Clinical oral investigations
|September 5, 2024
概括
牙周治疗显著减少系统性炎症标志物,如C反应蛋白 (CRP),在2型糖尿病患者 (T2DM). 这种改善是在短期内观察到的,可能会降低其他系统性疾病的风险.
科学领域:
- 牙周病学 牙周病学
- 内分泌学 在内分泌学.
- 生物标志物研究 生物标志物研究
背景情况:
- 2型糖尿病 (T2DM) 和牙周炎是普遍存在的疾病,通常是并存的.
- 系统性炎症和氧化应激与T2DM并发症的发病和进展有关.
- 牙周病可能会影响全身炎症标志物,影响T2DM管理.
研究的目的:
- 系统地审查牙周治疗对T2DM和牙周炎患者全身炎症和氧化应激生物标志物的影响.
- 评估非手术性牙周治疗对调节这些生物标志物的疗效.
主要方法:
- 在六个数据库,协议记录和其他来源进行了全面的电子搜索,直到2024年5月.
- 资格标准集中在随机对照试验中,评估牙周治疗对T2DM患者炎症参数的影响.
- 偏差风险和证据确定性分别使用RoB2和GRADE工具进行评估.
主要成果:
- 综述中包括了14项涉及1223名参与者的研究.
- 中等质量的证据表明,牙周治疗对T2DM患者的血清C反应蛋白 (CRP) 水平产生积极影响.
- 观察到CRP显著降低,特别是在吸烟者和治疗后六个月.
结论:
- 非手术性牙周治疗有效改善T2DM患者的短期系统性炎症生物标志物.
- 适度的证据支持高敏感性CRP血清水平的改善.
- 牙周治疗可能有助于降低T2DM患者的全身并发症风险,包括心血管疾病.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
01:29Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178